You are here: Industry Insights > Lung Cancer

News List

TAGRISSO granted FDA breakthrough therapy status in EGFR-mutated lung cancer pharmaceutical-business-review
August 05, 2020
AstraZeneca’s TAGRISSO (osimertinib) has been granted Breakthrough Therapy Designation (BTD) in the US for the adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer...
First Patient Enrolled in Pafolacianine Sodium Trial for Lung Cancer Lesions americanpharmaceuticalreview
July 20, 2020
On Target Laboratories has enrolled the first patient in the ELUCIDATE Trial, a Phase 3 clinical trial evaluating the efficacy and safety of pafolacianine sodium (formerly OTL38) in the intraoperative detection of lung cancer lesions.
Tagrisso shows 'unprecedented' disease free survival in lung cancer pharmatimes
June 01, 2020
According to AstraZeneca, its EGFR inhibitor Tagrisso (osimertinib) has shown 'unprecedented disease-free survival' in the adjuvant treatment of patients with EGFR-mutated lung cancer.
Researchers develop AI tool able to predict cancer relapse pharmatimes
May 29, 2020
A team of computer scientists and pathologists have trained an artificial intelligence (AI) tool to identify lung cancer patients who have a higher risk of disease recurrence following treatment.
AZ links with ArcherDX to detect minimal residual disease in lung cancer patients pharmatimes
May 27, 2020
AstraZeneca is teaming up with genomic analysis group ArcherDX to use personalised cancer monitoring to detect minimal residual disease (MRD) in patients with early-stage non-small cell lung cancer (NSCLC).
AZ/Daiichi Sankyo's Enhertu picks up third breakthrough designation pharmatimes
May 19, 2020
AstraZeneca's and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been granted Breakthrough Therapy Designation (BTD) in the US for the treatment of patients with a particular form of lung cancer.
FDA approves first targetted therapy to treat aggressive form of lung cancer expresspharma
May 07, 2020
The FDA also approved the FoundationOne CDx assay (F1CDx) as a companion diagnostic for Tabrecta.
Bristol Myers says Opdivo performs well in kidney, lung cancer trials expresspharma
April 22, 2020
Opdivo is one of Bristol’s top-selling drugs, but sales of the drug have slowed in recent years as it has been eclipsed by Merck & Co’s rival drug Keytruda.
NCCN, AstraZeneca Announce Lung Cancer Projects americanpharmaceuticalreview
March 05, 2020
The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) announced three research projects selected to receive funding to improve healthcare provider performance ...
Pulmatrix Announces Agreement with Lung Cancer Initiative americanpharmaceuticalreview
January 06, 2020
Pulmatrix has entered into a licensing and development agreement with the Lung Cancer Initiative at Johnson & Johnson. Through the agreement, the Lung Cancer Initiative gains an option to access a portfolio of narrow spectrum kinase inhibitors intended fo

Previous page 1 2 3 4 5 6 7 8 9 10 ... 15 16 Next page